Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception
| Autor: | Aron H. Lichtman, Lamont Booker, Anu Mahadevan, Raj K. Razdan, Pattipati S. Naidu |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Cannabinoid receptor medicine.drug_class medicine.medical_treatment Pain Motor Activity Pharmacology Toxicology Tetrahydrocannabivarin Article Receptor Cannabinoid CB2 Mice Cannabichromene chemistry.chemical_compound Piperidines Receptor Cannabinoid CB1 Rimonabant mental disorders medicine Animals Pharmacology (medical) Dronabinol RNA Messenger Acetic Acid Pain Measurement Analgesics Mice Inbred ICR Camphanes Dose-Response Relationship Drug Cannabinoids organic chemicals Cyclohexanols Receptor antagonist Psychiatry and Mental health chemistry Anesthesia Cannabinol Pyrazoles Anti-Obesity Agents Cannabinoid Cannabidiol medicine.drug |
| Zdroj: | Drug and Alcohol Dependence. 105:42-47 |
| ISSN: | 0376-8716 |
| Popis: | Considerable preclinical research has demonstrated the efficacy of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive constituent of Cannabis sativa, in a wide variety of animal models of pain, but few studies have examined other phytocannabinoids. Indeed, other plant-derived cannabinoids, including cannabidiol (CBD), cannabinol (CBN), and cannabichromene (CBC) elicit antinociceptive effects in some assays. In contrast, tetrahydrocannabivarin (THCV), another component of cannabis, antagonizes the pharmacological effects of Delta(9)-THC. These results suggest that various constituents of this plant may interact in a complex manner to modulate pain. The primary purpose of the present study was to assess the antinociceptive effects of these other prevalent phytocannabinoids in the acetic acid stretching test, a rodent visceral pain model. Of the cannabinoid compounds tested, Delta(9)-THC and CBN bound to the CB(1) receptor and produced antinociceptive effects. The CB(1) receptor antagonist, rimonabant, but not the CB(2) receptor antagonist, SR144528, blocked the antinociceptive effects of both compounds. Although THCV bound to the CB(1) receptor with similar affinity as Delta(9)-THC, it had no effects when administered alone, but antagonized the antinociceptive effects of Delta(9)-THC when both drugs were given in combination. Importantly, the antinociceptive effects of Delta(9)-THC and CBN occurred at lower doses than those necessary to produce locomotor suppression, suggesting motor dysfunction did not account for the decreases in acetic acid-induced abdominal stretching. These data raise the intriguing possibility that other constituents of cannabis can be used to modify the pharmacological effects of Delta(9)-THC by either eliciting antinociceptive effects (i.e., CBN) or antagonizing (i.e., THCV) the actions of Delta(9)-THC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect